Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine if the Revian Red All LED cap shows potential to be an effective treatment for Central centrifugal cicatricial alopecia (CCCA) by recruiting hair follicles back to anagen growth or by improving inflammation. The primary outcome is to determine if hair loss regression is halted. Secondary outcomes include hair regrowth and alleviation of signs and symptoms of the disease. Participants will be asked to use the Revian Red All LED cap once daily for a 10-minute treatment regimen which is the current androgenetic alopecia recommendation.


Clinical Trial Description

Subjects who are willing to participate in a novel treatment for Revian Red All LED cap will be enrolled in this study. The cap uses two wavelengths of light, 620 nm and 660 nm. A study cap will be provided for each subject. Subjects will use the cap once daily, 10-minute treatment regimen which is the current androgenetic alopecia recommendation. The subjects will use the cap for a total of 6 months. To use the cap, subjects will connect the Revian Red All LED cap to a Smart App on a mobile phone device using Bluetooth. Subjects can use the Smart App to set daily reminders to use the cap, track and log usage, and use the 10 minute timer. No additional information will be stored on the Smart App. Only subjects will have access to the Smart App located on their personal mobile phone device. Standardized photos and trichoscopic photos before starting treatment and every 2 months for x 6 total months will be taken to assess hairline stabilization and potential for regrowth. A baseline photo and completion photo will also be taken with a visio device. This will help determine pigmentation of the present hairs throughout the study. Prior to study enrollment, all participants will receive a detailed explanation of the purpose of the study and will undergo written informed consent. Clinical history of hair loss and history of prior treatment will be obtained by administering a standardized questionnaire to all subjects. Subjects will also fill out a questionnaire regarding symptoms of their hair loss at each visit. There will be 4 visits total (1 Pre-treatment visit and 3 Follow up visits). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05759338
Study type Interventional
Source Wake Forest University Health Sciences
Contact Ivie M Obeime, D.O.
Phone 336-716-3926
Email iobeime@wakehealth.edu
Status Recruiting
Phase N/A
Start date July 10, 2023
Completion date November 2024

See also
  Status Clinical Trial Phase
Completed NCT03521687 - Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Phase 4
Not yet recruiting NCT05416333 - Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) Early Phase 1
Recruiting NCT04764331 - A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia N/A
Completed NCT03346668 - Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia Early Phase 1
Withdrawn NCT05416320 - Calcipotriol as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) Early Phase 1
Completed NCT03044782 - Barriers to Care and QOL for CCCA Patients N/A
Completed NCT04342091 - Follicular Revival in Fibrosing Alopecia: Evaluating Use of Micro-needling N/A